Clinical Trial Update: SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is investigating the combination of SX-682 with atezolizumab for advanced, metastatic, or recurrent non-small cell lung cancer, and the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• SX-682

Snippet

Sponsor: University of Washington | Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING